If you think this trial is relevant to your situation, please contact your Cancer Specialist to discuss further.
BIOMARCER-2 – Biomarker informed optimal management of advanced RAS wild type colorectal cancer in right sided disease
Purpose of the Study
Choosing the optimal therapy for patients with metastatic colorectal cancer is challenging. A number of factors are taken into consideration when selecting the most appropriate treatment plan, and include prior treatment, RAS/BRAF mutation status, mismatch repair status and primary tumour location.
This study will test colorectal tumour samples for a prognostic biomarker expression called amphiregulin (AREG) and epiregulin (EREG). These biomarkers indicate a possible sensitivity to cancer treatment known as anti-EGFR treatment. Patients who are determined to have high AREG and/or EREG expression levels for right sided RAS/BRAF wild-type, metastatic colorectal cancer will receive targeted treatment with anti-EGFR therapy. The study aims to demonstrate the progression free survival (PFS) benefit in those patients receiving anti-EGFR based treatment in the 2nd or later line setting.
DETAILED INFORMATION AVAILABLE
More detailed information to come.
Dr Shehara Mendis
Professor Peter Gibbs
2021 Innovation Grant
If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.